Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Poyurovsky, M. Articles by Weizman, A. Search for Related Content PubMed Citation Articles by Poyurovsky, M. Articles by Weizman, A. Atypical Neuroleptics Antidepressants

Olanzapine-Induced Weight Gain in Patients With First-Episode Schizophrenia: A Double-Blind, Placebo-Controlled Study of Fluoxetine Addition

OBJECTIVE: Since olanzapine-induced weight gain may be attributable to the antagonistic activity of olanzapine at the serotonin-2C receptor, the authors hypothesized that it might be attenuated by addition of the selective serotonin reuptake inhibitor fluoxetine. METHOD: First-episode hospitalized schizophrenia patients (N=30) were randomly assigned in an 8-week double-blind study of olanzapine, 10 mg/day, coadministered with either fluoxetine, 20 mg/day (N=15), or placebo (N=15). RESULTS: The group receiving olanzapine plus fluoxetine showed significantly less improvement in positive and disorganized symptom dimensions than the group receiving olanzapine plus placebo. The two groups demonstrated similar and substantial gradual weight gains. CONCLUSIONS: These results suggest that fluoxetine coadministration is clinically ineffective and cannot attenuate olanzapine-induced weight gain.

This article has been cited by other articles:

				M. Malone Medications Associated with Weight Gain Ann. Pharmacother., December 1, 2005; 39(12): 2046 - 2054. [Abstract] [Full Text] [PDF]

				L. E. Jones and C. P. Carney Mental Disorders and Revascularization Procedures in a Commercially Insured Sample Psychosom Med, July 1, 2005; 67(4): 568 - 576. [Abstract] [Full Text] [PDF]

				D. C. Henderson, P. M. Copeland, T. B. Daley, C. P. Borba, C. Cather, D. D. Nguyen, P. M. Louie, A. E. Evins, O. Freudenreich, D. Hayden, et al. A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain Am J Psychiatry, May 1, 2005; 162(5): 954 - 962. [Abstract] [Full Text] [PDF]

				E K. Hester and M. R Thrower Current Options in the Management of Olanzapine-Associated Weight Gain Ann. Pharmacother., February 1, 2005; 39(2): 302 - 310. [Abstract] [Full Text] [PDF]

				J. Mintzer and S. D. Targum Psychosis in Elderly Patients: Classification and Pharmacotherapy J Geriatr Psychiatry Neurol, December 1, 2003; 16(4): 199 - 206. [Abstract] [PDF]

				M. Poyurovsky, I. Isaacs, C. Fuchs, M. Schneidman, S. Faragian, R. Weizman, and A. Weizman Attenuation of Olanzapine-Induced Weight Gain With Reboxetine in Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Study Am J Psychiatry, February 1, 2003; 160(2): 297 - 302. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us